Relation Between Plasma Ceramides and Cardiovascular Death in Chronic Heart Failure: A Subset Analysis of the GISSI-HF Trial — Giovanni Targher (2020) | RDL Network
Relation Between Plasma Ceramides and Cardiovascular Death in Chronic Heart Failure: A Subset Analysis of the GISSI-HF Trial
Article 2020 en
Authors
GT
Giovanni Targher
GL
Gianluigi Lunardi
AM
Alessandro Mantovani
Abstract
1 min read
Higher levels of specific plasma ceramides [especially when used in ratios with Cer(d18:1/24:0)] are associated with increased cardiovascular mortality in ambulatory patients with chronic HF. However, these associations are weakened after adjustment for established cardiovascular risk factors, medication use, and plasma NT-proBNP concentrations.
Chiara Signori, Jennifer Meessen, Reijo Laaksonen, Aldo Maggioni, Deborah Novelli, Adriana Blanda, Antti Jylhä, Enrico Nicolis, Giovanni Targher, Luigi Tavazzi, Gianni Tognoni, Mika Hilvo, Roberto Latini
Inder S. Anand, Changhong Yu, Marc A. Pfeffer, John J.V. McMurray, Akshay S. Desai, Scott D. Solomon, Dirk J. ban Veldhuisen, Sunfa Cheng, Kurt Olson, Aldo Maggioni, Karl Swedberg, James B. Young
Sharda S. Anroedh, Mika Hilvo, K. Martijn Akkerhuis, Dimple Kauhanen, Kaisa M. Koistinen, Rohit M. Oemrawsingh, Patrick W. Serruys, Robert‐Jan van Geuns, Eric Boersma, Reijo Laaksonen, Isabella Kardys
Discussion(0)
No comments yet. Be the first to comment.